Previous 10 | Next 10 |
Summary There is a high chance that the Illumina, Inc.-Grail deal would collapse after European regulators decide to block the acquisition. Without Grail, I believe Illumina will find it hard to maintain growth in light of disruptions in its end markets, namely the clinical gene t...
Summary As the era of free money comes to an end, the gene testing industry is faced with the challenge of transforming itself into a commercially viable sector. Though it is still early days for the industry, major players have embarked on restructuring efforts to transform thems...
Exact Sciences Demonstrates Power of Multi-Cancer Early Detection Approach with Data Presentation at the 2022 European Society for Medical Oncology Congress PR Newswire Multi-Biomarker Approach Achieves 61 Percent Sensitivity for Cancer at an Overall Specificity of 9...
Summary We indicated in our previous update that we needed to observe more constructive bottoming action in ARKK before we would consider re-rating it. We are pleased to highlight that ARKK has likely bottomed out decisively in May. Coupled with a likely peak inflationary environm...
Growth stocks associated with innovative healthcare businesses aren't getting the positive attention they deserve. At least that's what Cathie Wood's recent purchases suggest. Recently, the CEO of ARK Investment Management added heavily to Exact Sciences (NASDAQ: EXAS) , CareD...
Biotech stocks have rallied huge after forming a bullish technical pattern earlier this quarter. One domestic biotech name has not participated in the industry's big speculative bounce, however. Exact Sciences features earnings that are in the red and the chart suggests more pain ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cathie Wood’s exchange-traded funds (ETFs) received a breath of fresh air this week. The ARK Innovation ETF (NYSEMKT: ARKK ) ended the period up over 12%. Wood did admit that she believes the U.S. is current...
Image source: The Motley Fool. Exact Sciences (NASDAQ: EXAS) Q2 2022 Earnings Call Aug 02, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Exact Sciences (EXAS) Q2 2022 Earnings Call Transcript
Exact Sciences Corporation (EXAS) Q2 2022 Earnings Conference Call August 02, 2022 05:00 PM ET Company Participants Megan Jones - Senior Director, Investor Relations Kevin Conroy - Chairman & Chief Executive Officer Jeff Elliott - Chief Financial Officer &...
MDxHealth SA ( NASDAQ: MDXH ) has acquired the Oncotype DX GPS (Genomic Prostate Score) test from Exact Sciences ( NASDAQ: EXAS ) as well as the latter's urology sales and marketing team. Under the deal, MDxHealth ( MDXH ) paid $25M in cash, plus anothe...
News, Short Squeeze, Breakout and More Instantly...
Exact Sciences Corporation Company Name:
EXAS Stock Symbol:
NASDAQ Market:
Exact Sciences Corporation Website:
2024-07-11 08:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-08 08:30:00 ET To say that Exact Sciences (NASDAQ: EXAS) hasn't performed well on the stock market this year would be an understatement. Shares of the cancer-focused biotech are down by 41%. However, the healthcare company still has some fans on Wall Street. Cathie Wood ...
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2024 financial results after the close of the U.S. financial markets on July 31, 2024. Following the release, company management w...